Loading data for DRTS — first visit, this takes a few seconds.

알림

Alpha Tau Medical Ltd. (DRTS)

NasdaqCM: DRTS · 실시간 가격 · USD

14.26

+0.11 (0.78%)

종가 기준: Aug 18, 2026, 3:59 PM

14.49

+1.61%

프리마켓: 7:38 AM

0.78% (1D)

매수호가	10.27
시가총액	1.32B
매출 (ttm)	n/a
순이익 (ttm)	-92.57M
베타	1.19
EPS (ttm)	-1.04
P/E (ttm)	n/a
선행 P/E	-27.07
P/B (ttm)	18.54
P/S (ttm)	n/a
Earnings Date	Nov 19, 2026

매도호가	17.94
거래량	369,508
평균 거래량 (20일)	798,550
시가	14.00
전일 종가	14.15
일중 범위	13.77 - 14.57
52주 범위	3.03 - 14.75
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

DRTS 소개

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Mar 8, 2021

직원 수 121

상장 거래소 NasdaqCM

티커 DRTS

웹사이트 https://www.alphatau.com

전체 기업 정보

재무 실적

2025년 Alpha Tau Medical의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -42.63M로, 34.26% 증가했습니다.

재무제표

어닝 서프라이즈

Alpha Tau Medical가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.5 예상치 하회 -0.36, 및 -284.62% 전년 대비 감소.

다음 실적 발표

Alpha Tau Medical Ltd.의 실적 발표 예정일은 Nov 19, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · Simply Wall St.

Alpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Success In Alpha DaRT Combo Trial

In July 2026, Alpha Tau Medical reported positive podium-presented data from a single-center trial showing that its Alpha DaRT device combined with pembrolizumab achieved a 100% objective response rat...

1개월 전 · Zacks

New Strong Sell Stocks for July 7th

AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.

1개월 전 · Zacks

New Strong Sell Stocks for July 2nd

DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.

1개월 전 · Simply Wall St.

Alpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform

Alpha Tau Medical recently reported that its Alpha DaRT technology was used to safely treat a recurrent glioblastoma patient in Israel, marking the first intracranial application of its brain-specific...

2개월 전 · Stocktwits

DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing

Alpha Tau signed an agreement with Tolmar to commercialize its lead cancer therapy for prostate cancer in the United States.

2 페이지 중 1

Alpha Tau Medical Ltd. (DRTS)